EICHORPublic-registry site landscape for NCT03850795, “HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)”, a Prostate Cancer Metastatic study sponsored by Hinova Pharmaceuticals USA, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03850795 (registry record) |
| Study title | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| Official title | PROCADE: A Multinational Phase 3, Randomized, Double-Blind, Non-inferiority, Efficacy and Safety Study of Oral HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
| Sponsor | Hinova Pharmaceuticals USA, Inc. |
| Condition(s) | Prostate Cancer Metastatic; Castration-resistant Prostate Cancer |
| Phase | PHASE3 |
| Listed sites | 58 |
| Intervention(s) | HC-1119, Enzalutamide |
| Site countries | United States, Australia, Austria, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Poland, Russia |
Patient-friendly overview of this study: eichor.com/study/NCT03850795.
Eichor generates a preliminary site-risk snapshot for NCT03850795 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
